AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
158.25
+1.91 (+1.22%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close156.34
Open157.03
Bid0.00 x 800
Ask162.41 x 800
Day's Range156.75 - 158.64
52 Week Range114.27 - 197.00
Volume3,024,148
Avg. Volume4,959,225
Market Cap51.911B
Beta (3Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-25.50
Earnings DateOct 28, 2019 - Nov 1, 2019
Forward Dividend & Yield2.96 (1.88%)
Ex-Dividend Date2019-08-12
1y Target Est181.38
Trade prices are not sourced from all markets
  • AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?
    Investor's Business Daily

    AbbVie Stock Is Poised To Become A Top 5 Pharma — But Should You Buy It?

    AbbVie stock fell on its $63 billion plan to acquire Botox-maker Allergan, which helps the pharmaceutical company diversify as Humira patents expire. So, is ABBV stock a buy right now?

  • Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions
    Investor's Business Daily

    Obesity Epidemic Leads To A New Problem — And It Could Be Worth Billions

    The NASH liver disease treatment market is growing with biotech companies like Intercept and Genfit in late-stage tests. Experts say the market for a successful drug could be worth billions.

  • Seth Klarman's Baupost Boosts Liberty, Reduces eBay
    GuruFocus.com

    Seth Klarman's Baupost Boosts Liberty, Reduces eBay

    Baupost had a busy 2nd quarter, according to its 13-F filing Continue reading...

  • Financial Times

    Correction: Allergan sale

    Allergan chief executive Brent Saunders disclosed the role of JPMorgan and Wachtell, Lipton, Rosen & Katz asadvisers to the company on its planned sale to AbbVie, not AbbVie chief executive Richard Gonzalez ...

  • Financial Times

    Elliott bags Goldman’s Barg

    Top advisory shops, including the likes of Goldman Sachs and Morgan Stanley, have long shunned activists for fear of alienating their corporate clients. As a result, shareholder activism has become a lucrative business for banks hoping to cosy up to corporates in search of future business and hefty fees.

  • Implied Volatility Surging for Allergan (AGN) Stock Options
    Zacks

    Implied Volatility Surging for Allergan (AGN) Stock Options

    Investors need to pay close attention to Allergan (AGN) stock based on the movements in the options market lately.

  • Here's Why Amgen Stock is Outperforming Its Industry Of Late
    Zacks

    Here's Why Amgen Stock is Outperforming Its Industry Of Late

    Favorable patent ruling related to Enbrel and strong second-quarter results drive Amgen (AMGN) stock 22.6% higher in the past three months.

  • Can Value Investors Consider Allergan (AGN) a Worthy Pick?
    Zacks

    Can Value Investors Consider Allergan (AGN) a Worthy Pick?

    Allergan (AGN) stock may be a good choice for value-oriented investors right now from multiple angles.

  • Financial Times

    JPMorgan Chase set to scoop record fee for Allergan sale

    JPMorgan Chase is poised to collect the largest individual fee to a bank for selling a company, earning $123m for advising Botox-maker Allergan on a planned $63bn sale to US pharmaceutical group AbbVie. the $120m paid to Morgan Stanley for advising US agribusiness Monsanto on its $66bn sale to Germany’s Bayer in 2016, according to data from Dealogic. The details of the fee arrangement were disclosed by Allergan this week as it prepares for a shareholder vote on its sale to Chicago-based AbbVie.

  • Reuters

    UPDATE 1-Evolus reports sales of its Botox rival ahead of expectations

    Medical aesthetics company Evolus Inc on Monday beat Wall Street estimates for second-quarter revenue from its newly launched rival to Allergan Plc's Botox, which has dominated the medical aesthetics market for more than a decade. "We did not anticipate revenue coming in the second quarter in a meaningful way," Chief Executive Officer David Moatazedi told Reuters in an interview. Evolus, whose shares rose 1.6% in premarket trading, expects to achieve the number two market position in the next 24 months.

  • Reuters

    Evolus says launch of its Botox rival ahead of its expectations

    Evolus Inc on Monday reported revenue of $2.3 million from early sales of its newly launched rival to Allergan Plc's Botox, ahead of its own expectations. Jeuveau, a neurotoxin drug to treat forehead wrinkles, was launched on May 15 and competes with Botox, which has grown to dominate the medical aesthetics market since it was launched in 2002. Evolus has rolled out a marketing program called J.E.T (Jeuveau Experience Treatment) that ties up with medical aesthetics clinics to provide new customers with up to three shipments of the treatment for free.

  • Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients
    Zacks

    Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients

    Allergan (AGN) and Novo Nordisk (NVO) report Q2 results. AbbVie's (ABBV) Maviret and Sanofi's (SNY) Dupixent receive approval for new patient population in Europe.

  • Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down
    Zacks

    Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

    Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

  • Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO
    Zacks

    Editas (EDIT) Misses on Q2 Earnings & Sales, Gets New CEO

    In the absence of an approved product in Editas' (EDIT) portfolio, pipeline development remains in focus on the second-quarter earnings call.

  • Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie
    Motley Fool

    Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie

    The drugmaker's Q2 revenue and earnings beats enable it to raise full-year guidance.

  • Allergan beats second-quarter expectations, boosts full-year guidance
    MarketWatch

    Allergan beats second-quarter expectations, boosts full-year guidance

    Growth in sales of anti-wrinkle treatment Botox and dermal filler Juvaderm helped drive Allergan Plc to an earnings beat on Tuesday, but gains were offset by a decline in Restasis and CoolSculpting sales.

  • Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up
    Zacks

    Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

    Botox, Juvederm fillers, Vraylar and Ozurdex drive Allergan's (AGN) second-quarter sales, making up for loss of exclusivity on some brands and lower sales of Restasis and textured breast implants.

  • Company News For Aug 6, 2019
    Zacks

    Company News For Aug 6, 2019

    Companies in the news are: AGN, ENR, EPC and MNK

  • Allergan (AGN) Surpasses Q2 Earnings and Revenue Estimates
    Zacks

    Allergan (AGN) Surpasses Q2 Earnings and Revenue Estimates

    Allergan (AGN) delivered earnings and revenue surprises of 0.92% and 3.89%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    Allergan Reports Q2 Earnings Beat, Reaffirms Guidance

    Allergan (NYSE: AGN ) reported second-quarter earnings of $4.38 per share, which beat the analyst consensus estimate of $4.34 by 0.92%. This is a 0.9% decrease over earnings of $4.42 per share from the ...

  • MarketWatch

    Allergan reports second-quarter earnings beat

    Allergan Plc reported second-quarter earnings on Tuesday that beat Wall Street expectations. The company reported a loss of $1.759 billion, or a loss of $5.37 a share, compared with a loss of $472.5 million, or a loss of $1.39 a share, one year ago. Adjusted EPS was $4.38 a share, topping the FactSet consensus of $4.35 a share. Allergan said it had recorded a pre-tax impairment charge of $1.65 billion in the latest quarter, which included a goodwill impairment of $1.09 billion that the company said was primarily due to delays in in clinical studies and a reduction in the expected value of some R&D projects. Revenue from the latest quarter was $4.09 billion, down slightly from $4.12 billion a year ago, but still ahead of the FactSet consensus of $3.935 billion. Botox sales rose 4.2% to $974 million, while sales of Restasis fell 3.4% to $322.8 million. Revenue from Juvaderm rose 11.3% to $329.3 million. The company raised its full-year revenue guidance to between $15.425 billion and $15.625 billion from between $15.125 billion and $15.425 billion. Shares of Allergan have gained 20.2% in the year to date through Monday, while the S&P 500 has gained 13.5%.

  • PR Newswire

    Allergan Reports Second Quarter 2019 Financial Results

    - Q2 2019 GAAP Net Revenues of $4.09 Billion - - Q2 2019 GAAP Loss Per Share of $5.37 ; Non-GAAP Performance Net Income Per Share of $4.38 - - Q2 2019 GAAP Operating Loss of $1.26 Billion ; Non-GAAP Operating ...

  • TheStreet.com

    Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

    Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.